Drugs / palmitoleic acid
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT07417696 | Apr 2026 → Mar 2029 expected | Crohn disease | Chinese Medical Association | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07547254 | Dec 2025 → Jun 2026 overdue | decubitus ulcer | Ruijin Hospital | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | palmitoleic acid | “a topical palmitoleic acid (POA) oil composition” NCT07547254 ↗ |
| Known as | POA | “a topical palmitoleic acid (POA) oil composition” NCT07547254 ↗ |
| Modality | Small molecule | — CHEMBL453509 ↗ |
| Route | Oral | “administered oral palmitoleic acid” NCT07417696 ↗ |